IDEAYA Receives FDA Priority Review for Uveal Melanoma Drug

IDEAYA Biosciences announced that it will submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its drug candidate developed to treat uveal melanoma. The company stated that it has received priority review status from the FDA for this application. Priority review status is granted to drugs that show potential for significant improvement over existing options in the treatment of a serious disease. This status allows the FDA to review the application within six months instead of the standard ten months. Uveal melanoma is a rare type of cancer that occurs in the middle layer of the eye (uvea). IDEAYA's drug aims to offer a new treatment option for this disease. If the NDA is accepted, the company will have taken a significant step toward bringing the drug to market. With this development, IDEAYA aims to expand its oncology portfolio and increase treatment options for rare cancers. The company's shares rose in pre-market trading following the news. This is not investment advice.